Navigation Links
Device prevents potential errors in children's medications

ANN ARBOR, Mich.---A device designed to eliminate mistakes made while mixing compounds at a hospital pharmacy was 100 percent accurate in identifying the proper formulations of seven intravenous drugs.

Five potentially serious medication errors were averted over an 18-month period in a test at C.S. Mott Children's Hospital in the University of Michigan Health System by using the technology, said Jim Stevenson, associate dean of Clinical Sciences at the U-M College of Pharmacy. Stevenson also directs Pharmacy Services at the U-M Health System.

Stevenson said the hospital is the first in the world to use this device to test patient drugs compounded in the pharmacy. The U-M Health System already has many safeguards, such as bar coding, in place to avert mistakes.

"Errors in compounding these types of medications are rare. However, when they occur they can have a significant negative impact on patients and staff," Stevenson said. "We know from having this technology in place we've deterred five errors that might have happened. I really believe having technology like this needs to be the standard around the country."

The table-top device manufactured by ValiMed, a division of Tuscon, Ariz.,-based CDEX Inc., uses a technique called enhanced photoemission spectroscopy to determine if the compounds are correct. Light is shot into the drug compound, which excites molecules, and the energy emitted by the excited molecules is measured by a spectrometer. Each drug compound tested has its own so-called light fingerprint, which is compared to the fingerprint of the control compound. If they match, the drug is considered correct.

There are many potential safeguards that are being pursued to improve medication safety, Stevenson said. However, the primary safeguard for intravenous drugs compounded in hospital pharmacies today remains a visual check by the pharmacist. Using a technology like this helps prevent mistakes that can occur due to human error, he said.

"Our goal needs to be to have zero tolerance for errors," Stevenson said. "If we wanted to eliminate errors completely we knew we couldn't continue to rely completely on human visual checking. We needed to implement some sort of technological solution to overlay our human process for these drugs to be failsafe."

The hospital tested 40-50 samples daily, at strengths and at variations below and above the proper dosage amount. The process takes about a minute, so the technology was able to be integrated into the workflow of the pharmacy when used for select high risk products, the paper said. The paper, "Enhanced photoemission spectroscopy for verification of high-risk IV medications," appears in the Jan. 1 issue of the American Journal of Health System Pharmacy.

The device is now used at C.S. Mott and University Hospital, both in the U-M Health System. The next step, Stevenson said, is for the company to develop more signatures so that more drugs can be tested

The idea for the project started in 2004 when Stevenson learned that a colleague at the University of Utah was using a similar device to test narcotics being returned in their operating room. Stevenson contacted the company about developing applications to check intravenous drug compounds prepared in the pharmacy for accuracy.


Contact: Laura Bailey
University of Michigan

Related biology news :

1. Device helps patients survive, regain function til transplant
2. Researchers developing device to predict proper light exposure for human health
3. IGERT fellows to design biodevices using flexible electronics
4. MIT aids creation of neural prosthetic devices
5. Atmospheric measuring device for understanding smog formation
6. EMD Serono launches easypod, new electronic growth hormone injection device
7. Better protection for biomedial devices could result from Rutgers-Camden research
8. Implanting embryonic cardiac cells prevents arrhythmias
9. Pittsburgh scientists identify human source of stem cells with potential to repair muscle
10. Neuronal conduction of excitation without action potentials based on ceramide production
11. To maximize biofuel potential, researchers look for sorghums sweet spot
Post Your Comments:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology: